Online Exclusive Article

Metastatic Colorectal Cancer: Management With Trifluridine/Tipiracil

Teresa White

Heidi Larson

Alexandra Minnella

Howard S. Hochster

adverse effects, trifluridine/tipiracil, TAS-102, metastatic colorectal cancer
CJON 2017, 21(2), E30-E37. DOI: 10.1188/17.CJON.E30-E37

Background: Treatment-related adverse events (AEs) are common in patients with metastatic colorectal cancer (mCRC) receiving chemotherapy. These AEs may affect patient adherence, particularly with completely oral regimens, such as trifluridine/tipiracil (TAS-102, Lonsurf®), an antimetabolite agent for patients with mCRC refractory or intolerant to standard therapies.

Objectives: This article reviews strategies for promoting adherence and educating patients and caregivers about oral therapy with trifluridine/tipiracil.

Methods: Recommended strategies for managing AEs are reviewed, with a focus on the most common AEs reported in patients with mCRC receiving trifluridine/tipiracil in clinical trials.

Findings: Oncology nurses play an important role in educating and counseling patients regarding treatment and its potential side effects. Among patients with mCRC refractory or intolerant to standard therapies, trifluridine/tipiracil was found to have a favorable safety profile. It is associated with hematologic AEs as well as a low incidence of nausea, diarrhea, vomiting, anorexia, and fatigue.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.